There was a trend toward higher baseline surface expression of PD-L1 and MHC-I proteins in lung cancer cell lines sensitive to Erlotinib, and significantly increased expression of MHC-I, MHC-II, and PD-L1 in response to IFNγ in lung cancer cell lines sensitive to erlotinib when compared to those resistant to erlotinib. This evidence concerns the gene IFNG and lung carcinoma.